Quantcast

Latest Oncothyreon Inc. Stories

2014-08-11 16:28:11

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the second quarter ended June 30, 2014. Loss from operations decreased to $7.8 million for the three months ended June 30, 2014 compared with $18.0 million for the comparable period in 2013, and decreased to $15.0 million for the six months ended June 30, 2014 compared with $26.0 million for the comparable period...

2014-08-11 16:28:00

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious Diseases Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately...

2014-08-04 08:27:57

SEATTLE, Aug. 4, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Monday, August 11, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its second quarter 2014 financial results and provide a corporate update and review of its pipeline of products in development. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will...

2014-06-02 08:30:18

SEATTLE, June 2, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of data from a Phase 1 trial of ONT-10, an antigen-specific immunotherapy targeting MUC1, at the American Association of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with...

2014-05-29 08:29:44

SEATTLE, WA and HAMPTON, NJ, May 29, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Celldex Therapeutics, Inc., (NASDAQ: CLDX) today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The planned trial is an...

2014-05-28 16:27:14

SEATTLE, WA, May 28, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference in New York on Wednesday, June 4, 2014 at 9 a.m. Eastern. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is a...

2014-05-01 16:33:05

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, May 1, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the first quarter ended March 31, 2014. Loss from operations was $7.2 million for the first quarter ended March 31, 2014 compared with $8.0 million for the first quarter ended March 31, 2013. The decrease in loss from operations was primarily due to a $1.0 million decrease in research and development expenses for the...

2014-04-24 08:34:29

SEATTLE, April 24, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, May 1, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its first quarter 2014 financial results and provide a review of its pipeline of products in development. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and...

2014-04-07 08:29:14

SEATTLE, April 7, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide...

2014-03-13 16:28:08

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, March 13, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the year and quarter ended December 31, 2013. Loss from operations was $41.2 million for the year ended December 31, 2013 compared with $28.5 million for the year ended December 31, 2012. The increase in loss from operations resulted primarily from an increase in research and development expenses to $33.2 million...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related